Newly developed retatrutide, a dual -action medication targeting simultaneously GLP-1 and GIP receptors, is creating considerable excitement within the healthcare community. Initial clinical studies have demonstrated impressive reductions in overall mass and improvements in physiological markers for patients with excess weight . Researchers bel… Read More